AXL and lung carcinoma: Moreover, studies in pancreatic and lung carcinoma models combining Axl inhibitors (e.g., SKI-G-801, BGB324) with standard chemotherapy and anti–PD–1 therapy have shown enhanced tumor control, associated with increased memory T cells and activated macrophages, alongside a reduction in regulatory T cells [66].